Symbiotic Health develops transformative microbiome-based therapies to address critical public health challenges.
Symbiotic Health develops transformative microbiome-based therapies to address critical public health challenges. The company develops a proprietary oral enteric delivery platform for biologics and cells. The process maintains the therapeutic agents in their solubilized or hydrated state, avoiding losses in functional activity through processing or gastrointestinal transit.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Sep 4, 2015 | Seed | $500K | 2 | — | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
the Long Island Emerging technologies Fund (LIETF) | — | Seed |
Accelerate Long Island | — | Seed |